Neuro-Oncology Reviews

Volume 24 Number 21
15 November 2022

Home > Publications > Neuro-Oncology Reviews > Volume 24, Year 2022 > Number 21, 15 November

Aiyappa-Maudsley R, Chalmers AJ, Parsons JL.
Factors affecting the radiation response in glioblastoma.
Neurooncol Adv. 2022 Sep 25, 2022;4(1):vdac156. doi: 10.1093/noajnl/vdac156. PMID: 36325371. Review.

Fougner V, Hasselbalch B, Lassen U, Weischenfeldt J, Poulsen HS, Urup T.
Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation.
Neurooncol Adv. 2022 Sep 28, 2022;4(1):vdac157. doi: 10.1093/noajnl/vdac157. PMID: 36325372. Review.

Miller R, Niazi M, Russial O, Poiset S, Shi W.
Tumor treating fields with radiation for glioblastoma: a narrative review.
Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90. PMID: 36336899. Review.

Mahmoud AB, Ajina R, Aref S, Darwish M, Alsayb M, Taher M, AlSharif SA, Hashem AM, Alkayyal AA.
Advances in immunotherapy for glioblastoma multiforme.
Front Immunol. 2022 Oct 12, 2022;13:944452. doi: 10.3389/fimmu.2022.944452. PMID: 36311781. Review.

Marabitti V, Giansanti M, De Mitri F, Gatto F, Mastronuzzi A, Nazio F.
Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma.
Front Cell Dev Biol. 2022 Oct 19, 2022;10:1007641. doi: 10.3389/fcell.2022.1007641. PMID: 36340043. Review.

Andersen BM, Reardon DA.
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials.
Curr Opin Neurol. 2022 Oct 21, 2022;35(6):803-813. doi: 10.1097/WCO.0000000000001118. PMID: 36367046. Review˰


Jovanovich N, Habib A, Head J, Anthony A, Edwards L, Zinn PO.
Opinion: Bridging gaps and doubts in glioblastoma cell-of-origin.
Front Oncol. 2022 Oct 21, 2022;12:1002933. doi: 10.3389/fonc.2022.1002933. PMID: 36338762. Opinion.

Mallick S, Benson R, Venkatesulu B, Melgandi W, Rath GK.
Systematic Review and Individual Patient Data Analysis of Uncommon Variants of Glioblastoma: An Analysis of 196 Cases.
Neurol India. 2022 Oct 21, 2022;70(5):2086-2092. doi: 10.4103/0028-3886.359222. PMID: 36352613. Review.

Lehrer EJ, Kowalchuk RO, Ruiz-Garcia H, Merrell KW, Brown PD, Palmer JD, Burri SH, Sheehan JP, Quninoes-Hinojosa A, Trifiletti DM.
Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas.
Front Surg. 2022 Oct 24, 2022;9:972727. doi: 10.3389/fsurg.2022.972727. PMID: 36353610. Review.

Ling SP, Ming LC, Dhaliwal JS, Gupta M, Ardianto C, Goh KW, Hussain Z, Shafqat N.
Role of Immunotherapy in the Treatment of Cancer: A Systematic Review.
Cancers (Basel). 2022 Oct 24, 2022;14(21):5205. doi: 10.3390/cancers14215205. PMID: 36358624. Review.

Lim YJ.
Medical Treatment of Pediatric Low-Grade Glioma.
Brain Tumor Res Treat. 2022 Oct 27, 2022;10(4):221-225. doi: 10.14791/btrt.2022.0039. PMID: 36347636. Review.

Schirrmacher V, van Gool S, Stuecker W.
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
Int J Mol Sci. 2022 Oct 27, 2022;23(21):13050. doi: 10.3390/ijms232113050. PMID: 36361831. Review.

Luo Y, Tian G, Fang X, Bai S, Yuan G, Pan Y.
Ferroptosis and Its Potential Role in Glioma: From Molecular Mechanisms to Therapeutic Opportunities.
Antioxidants (Basel). 2022 Oct 28, 2022;11(11):2123. doi: 10.3390/antiox11112123. PMID: 36358495. Review.

Catalano M, Serpe C, Limatola C.
Microglial Extracellular Vesicles as Modulators of Brain Microenvironment in Glioma.
Int J Mol Sci. 2022 Oct 29, 2022;23(21):13165. doi: 10.3390/ijms232113165. PMID: 36361947. Review.

Foo CY, Munir N, Kumaria A, Akhtar Q, Bullock CJ, Narayanan A, Fu RZ.
Medical Device Advances in the Treatment of Glioblastoma.
Cancers (Basel). 2022 Oct 29, 2022;14(21):5341. doi: 10.3390/cancers14215341. PMID: 36358762. Review.

Goldman M, Lucke-Wold B, Martinez-Sosa M, Katz J, Mehkri Y, Valisno J, Quintin S.
Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies.
Explor Target Antitumor Ther. 2022 Oct 31, 2022;3(5):659-675. doi: 10.37349/etat.2022.00106. PMID: 36338521. Review.

Szklener K, Mazurek M, Wieteska M, Wacławska M, Bilski M, Mańdziuk S.
New Directions in the Therapy of Glioblastoma.
Cancers (Basel). 2022 Oct 31, 2022;14(21):5377. doi: 10.3390/cancers14215377. PMID: 36358795. Review.

Onishi S, Ohba S, Kuraoka K, Kurashige T, Sugiyama K, Yamasaki F.
Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review.
Neurocirugia (Astur:Engl Ed). 2022 Nov 1, 2022;33(6):356-360. doi: 10.1016/j.neucie.2021.06.008. PMID: 36333093. Case report, Review˰

Wu L, Chai R, Zhao Z, Wang Q, Jiang T.
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies.
Cancer Biol Med. 2022 Nov 1, 2022;19(10):1423–7. doi: 10.20892/j.issn.2095-3941.2022.0363. PMID: 36350003. Editorial.

Haddad AF, Aghi MK, Butowski N.
Novel intraoperative strategies for enhancing tumor control: Future directions.
Neuro Oncol. 2022 Nov 2, 2022;24(S6):S25-S32. doi: 10.1093/neuonc/noac090. PMID: 36322096. Review.

Odia Y, Gutierrez AN, Kotecha R.
Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review. [GammaTile®]
Neuro Oncol. 2022 Nov 2, 2022;24(S6):S16-S24. doi: 10.1093/neuonc/noac130. PMID: 36322100. Review.

Schupper AJ, Chanenchuk T, Racanelli A, Price G, Hadjipanayis CG.
Laser hyperthermia: Past, present, and future. [LITT]
Neuro Oncol. 2022 Nov 2, 2022;24(S6):S42-S51. doi: 10.1093/neuonc/noac208. PMID: 36322099. Review.

Wu A, Wu JY, Lim M.
Updates in intraoperative strategies for enhancing intra-axial brain tumor control.
Neuro Oncol. 2022 Nov 2, 2022;24(S6):S33-S41. doi: 10.1093/neuonc/noac170. PMID: 36322098. Review.

Bahadur S, Prakash A.
A Comprehensive Review on Nanomedicine: Promising approach for treatment of brain tumor through intranasal administration.
Curr Drug Targets. 2022 Nov 3. doi: 10.2174/1389450124666221019141044. PMID: 36278468. Review˰

Khristov V, Lin A, Freedman Z, Staub J, Shenoy G, Mrowczynski O, Rizk E, Zacharia B, Connor J.
Tumor-derived Biomarkers in Liquid Biopsy of Glioblastoma.
World Neurosurg. 2022 Nov 5, 2022:S1878-8750(22)01554-6. doi: 10.1016/j.wneu.2022.11.012. PMID: 36347463. Review˰

Seliger C, Oppong FB, Lefranc F, Chinot O, Stupp R, Nabors B, Gorlia T, Weller M; EORTC Brain Tumor Group.
Research Article: Association of antidepressant drug use with outcome of patients with glioblastoma.
Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34344. PMID: 36346112. Pooled analysis.

Adnani L, Spinelli C, Tawil N, Rak J.
Role of extracellular vesicles in cancer-specific interactions between tumour cells and the vasculature.
Semin Cancer Biol. 2022 Nov 9, 2022:S1044-579X(22)00225-5. doi: 10.1016/j.semcancer.2022.11.003. PMID: 36371024. Review˰

Oztek MA, Noda SM, Romberg EK, Cole BL, Wright JN, Ishak GE, Perez FA.
Changes to pediatric brain tumors in 2021 World Health Organization classification of tumors of the central nervous system.
Pediatr Radiol. 2022 Nov 9. doi: 10.1007/s00247-022-05546-w. PMID: 36348014. Review˰

Chidley P, Shanker M, Phillips C, Haghighi N, Pinkham MB, Whittle JR, Sia J.
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
J Neurooncol. 2022 Nov 10, 2022:1–14. doi: 10.1007/s11060-022-04151-z. PMID: 36355260. Observational study, Meta-analysis.

Yang Y, Schubert MC, Kuner T, Wick W, Winkler F, Venkataramani V.
Brain Tumor Networks in Diffuse Glioma.
Neurotherapeutics. 2022 Nov 10. doi: 10.1007/s13311-022-01320-w. PMID: 36357661. Review.

Kizilbash SH.
Why has targeting EGFR aberrations in glioblastoma therapy had limited success?
Expert Rev Anticancer Ther. 2022 Nov 11. doi: 10.1080/14737140.2022.2146581. PMID: 36367033. Editorial.